The contraception needs of the perimenopausal woman
Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that m...
Gespeichert in:
| Veröffentlicht in: | Best practice & research. Clinical obstetrics & gynaecology 2014-08, Vol.28 (6), p.903-915 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 915 |
|---|---|
| container_issue | 6 |
| container_start_page | 903 |
| container_title | Best practice & research. Clinical obstetrics & gynaecology |
| container_volume | 28 |
| creator | Hardman, Sarah M.R., MB ChB, MFSRH Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH |
| description | Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that may be an alternative to sterilisation. Hormonal methods confer significant non-contraceptive benefits, and each individual woman should weigh up the benefits and risks of a particular method. No method of contraception is contraindicated by age alone, although combined hormonal contraception and injectable progestogens are not recommended for women over the age of 50 years. The intrauterine system has particular advantages as a low-dose method of effective hormonal contraception, which also offers control of menstrual dysfunction and endometrial protection in women requiring oestrogen replacement. Condoms are recommended for personal protection against sexually transmitted infections in new relationships. Standard hormone replacement therapy is not a method of contraception. |
| doi_str_mv | 10.1016/j.bpobgyn.2014.05.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1553106777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1521693414001060</els_id><sourcerecordid>1553106777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-f9ba535f523cf4fad784f5d211f4481aa23bfa2ff0bb962911a0cfe4c2ea2f333</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYoaBTwBlySahyo_0eANCI17SSCwY1pbjlMFN2g52Mqj_HkfdsGDDqqzyvfU4xdhzhA4B-1f7bpjT8O0YOw4oO1AdQP-AXaISvEUt-MPtzbHttZAX7EkpewAhNFeP2QWXWleXuGTi7js1LsUlW0fzElJsItFYmuSbpX7NlMOBYprtWuzU_EoHG5-yR95OhZ6d4xX7-v7d3c3H9vbzh083b29bJzUsrdeDVUJ5xYXz0ttxdy29Gjmil_IareVi8JZ7D8Oge64RLThP0nGqWSHEFXt5qjvn9HOlsphDKI6myUZKazGolEDod7tdlaqT1OVUSiZv5jq3zUeDYDZeZm_OvMzGy4AylVf1vTi3WIcDjX9dfwBVwZuTgOqi94GyKS5QdDSGTG4xYwr_bfH6nwpuCjE4O_2gI5V9WnOsFA2awg2YL9vRtpuhBKjbgfgN1uSTaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1553106777</pqid></control><display><type>article</type><title>The contraception needs of the perimenopausal woman</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hardman, Sarah M.R., MB ChB, MFSRH ; Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</creator><creatorcontrib>Hardman, Sarah M.R., MB ChB, MFSRH ; Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</creatorcontrib><description>Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that may be an alternative to sterilisation. Hormonal methods confer significant non-contraceptive benefits, and each individual woman should weigh up the benefits and risks of a particular method. No method of contraception is contraindicated by age alone, although combined hormonal contraception and injectable progestogens are not recommended for women over the age of 50 years. The intrauterine system has particular advantages as a low-dose method of effective hormonal contraception, which also offers control of menstrual dysfunction and endometrial protection in women requiring oestrogen replacement. Condoms are recommended for personal protection against sexually transmitted infections in new relationships. Standard hormone replacement therapy is not a method of contraception.</description><identifier>ISSN: 1521-6934</identifier><identifier>EISSN: 1532-1932</identifier><identifier>DOI: 10.1016/j.bpobgyn.2014.05.006</identifier><identifier>PMID: 24990143</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Condoms ; Contraception - adverse effects ; Contraception - methods ; Contraceptive Agents, Female - administration & dosage ; Contraceptive Agents, Female - adverse effects ; Contraceptives, Oral, Combined - administration & dosage ; Developed Countries ; Developing Countries ; Drug Implants ; Endometrial Neoplasms - prevention & control ; Female ; hormonal contraception ; Hormone Replacement Therapy ; Humans ; intra-uterine contraception ; Intrauterine Devices, Medicated ; Male ; non-contraceptive benefits ; Obstetrics and Gynecology ; Osteoporosis, Postmenopausal - prevention & control ; Ovarian Neoplasms - prevention & control ; Perimenopause ; Pregnancy ; Risk Assessment ; Vasectomy ; Venous Thromboembolism - etiology ; World Health Organization</subject><ispartof>Best practice & research. Clinical obstetrics & gynaecology, 2014-08, Vol.28 (6), p.903-915</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-f9ba535f523cf4fad784f5d211f4481aa23bfa2ff0bb962911a0cfe4c2ea2f333</citedby><cites>FETCH-LOGICAL-c490t-f9ba535f523cf4fad784f5d211f4481aa23bfa2ff0bb962911a0cfe4c2ea2f333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bpobgyn.2014.05.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24990143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hardman, Sarah M.R., MB ChB, MFSRH</creatorcontrib><creatorcontrib>Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</creatorcontrib><title>The contraception needs of the perimenopausal woman</title><title>Best practice & research. Clinical obstetrics & gynaecology</title><addtitle>Best Pract Res Clin Obstet Gynaecol</addtitle><description>Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that may be an alternative to sterilisation. Hormonal methods confer significant non-contraceptive benefits, and each individual woman should weigh up the benefits and risks of a particular method. No method of contraception is contraindicated by age alone, although combined hormonal contraception and injectable progestogens are not recommended for women over the age of 50 years. The intrauterine system has particular advantages as a low-dose method of effective hormonal contraception, which also offers control of menstrual dysfunction and endometrial protection in women requiring oestrogen replacement. Condoms are recommended for personal protection against sexually transmitted infections in new relationships. Standard hormone replacement therapy is not a method of contraception.</description><subject>Condoms</subject><subject>Contraception - adverse effects</subject><subject>Contraception - methods</subject><subject>Contraceptive Agents, Female - administration & dosage</subject><subject>Contraceptive Agents, Female - adverse effects</subject><subject>Contraceptives, Oral, Combined - administration & dosage</subject><subject>Developed Countries</subject><subject>Developing Countries</subject><subject>Drug Implants</subject><subject>Endometrial Neoplasms - prevention & control</subject><subject>Female</subject><subject>hormonal contraception</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>intra-uterine contraception</subject><subject>Intrauterine Devices, Medicated</subject><subject>Male</subject><subject>non-contraceptive benefits</subject><subject>Obstetrics and Gynecology</subject><subject>Osteoporosis, Postmenopausal - prevention & control</subject><subject>Ovarian Neoplasms - prevention & control</subject><subject>Perimenopause</subject><subject>Pregnancy</subject><subject>Risk Assessment</subject><subject>Vasectomy</subject><subject>Venous Thromboembolism - etiology</subject><subject>World Health Organization</subject><issn>1521-6934</issn><issn>1532-1932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYoaBTwBlySahyo_0eANCI17SSCwY1pbjlMFN2g52Mqj_HkfdsGDDqqzyvfU4xdhzhA4B-1f7bpjT8O0YOw4oO1AdQP-AXaISvEUt-MPtzbHttZAX7EkpewAhNFeP2QWXWleXuGTi7js1LsUlW0fzElJsItFYmuSbpX7NlMOBYprtWuzU_EoHG5-yR95OhZ6d4xX7-v7d3c3H9vbzh083b29bJzUsrdeDVUJ5xYXz0ttxdy29Gjmil_IareVi8JZ7D8Oge64RLThP0nGqWSHEFXt5qjvn9HOlsphDKI6myUZKazGolEDod7tdlaqT1OVUSiZv5jq3zUeDYDZeZm_OvMzGy4AylVf1vTi3WIcDjX9dfwBVwZuTgOqi94GyKS5QdDSGTG4xYwr_bfH6nwpuCjE4O_2gI5V9WnOsFA2awg2YL9vRtpuhBKjbgfgN1uSTaA</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Hardman, Sarah M.R., MB ChB, MFSRH</creator><creator>Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>The contraception needs of the perimenopausal woman</title><author>Hardman, Sarah M.R., MB ChB, MFSRH ; Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-f9ba535f523cf4fad784f5d211f4481aa23bfa2ff0bb962911a0cfe4c2ea2f333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Condoms</topic><topic>Contraception - adverse effects</topic><topic>Contraception - methods</topic><topic>Contraceptive Agents, Female - administration & dosage</topic><topic>Contraceptive Agents, Female - adverse effects</topic><topic>Contraceptives, Oral, Combined - administration & dosage</topic><topic>Developed Countries</topic><topic>Developing Countries</topic><topic>Drug Implants</topic><topic>Endometrial Neoplasms - prevention & control</topic><topic>Female</topic><topic>hormonal contraception</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>intra-uterine contraception</topic><topic>Intrauterine Devices, Medicated</topic><topic>Male</topic><topic>non-contraceptive benefits</topic><topic>Obstetrics and Gynecology</topic><topic>Osteoporosis, Postmenopausal - prevention & control</topic><topic>Ovarian Neoplasms - prevention & control</topic><topic>Perimenopause</topic><topic>Pregnancy</topic><topic>Risk Assessment</topic><topic>Vasectomy</topic><topic>Venous Thromboembolism - etiology</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hardman, Sarah M.R., MB ChB, MFSRH</creatorcontrib><creatorcontrib>Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Best practice & research. Clinical obstetrics & gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hardman, Sarah M.R., MB ChB, MFSRH</au><au>Gebbie, Ailsa E., MB ChB, FRCPG, FRCPE, FSRH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The contraception needs of the perimenopausal woman</atitle><jtitle>Best practice & research. Clinical obstetrics & gynaecology</jtitle><addtitle>Best Pract Res Clin Obstet Gynaecol</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>28</volume><issue>6</issue><spage>903</spage><epage>915</epage><pages>903-915</pages><issn>1521-6934</issn><eissn>1532-1932</eissn><abstract>Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that may be an alternative to sterilisation. Hormonal methods confer significant non-contraceptive benefits, and each individual woman should weigh up the benefits and risks of a particular method. No method of contraception is contraindicated by age alone, although combined hormonal contraception and injectable progestogens are not recommended for women over the age of 50 years. The intrauterine system has particular advantages as a low-dose method of effective hormonal contraception, which also offers control of menstrual dysfunction and endometrial protection in women requiring oestrogen replacement. Condoms are recommended for personal protection against sexually transmitted infections in new relationships. Standard hormone replacement therapy is not a method of contraception.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>24990143</pmid><doi>10.1016/j.bpobgyn.2014.05.006</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6934 |
| ispartof | Best practice & research. Clinical obstetrics & gynaecology, 2014-08, Vol.28 (6), p.903-915 |
| issn | 1521-6934 1532-1932 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1553106777 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Condoms Contraception - adverse effects Contraception - methods Contraceptive Agents, Female - administration & dosage Contraceptive Agents, Female - adverse effects Contraceptives, Oral, Combined - administration & dosage Developed Countries Developing Countries Drug Implants Endometrial Neoplasms - prevention & control Female hormonal contraception Hormone Replacement Therapy Humans intra-uterine contraception Intrauterine Devices, Medicated Male non-contraceptive benefits Obstetrics and Gynecology Osteoporosis, Postmenopausal - prevention & control Ovarian Neoplasms - prevention & control Perimenopause Pregnancy Risk Assessment Vasectomy Venous Thromboembolism - etiology World Health Organization |
| title | The contraception needs of the perimenopausal woman |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A38%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20contraception%20needs%20of%20the%20perimenopausal%20woman&rft.jtitle=Best%20practice%20&%20research.%20Clinical%20obstetrics%20&%20gynaecology&rft.au=Hardman,%20Sarah%20M.R.,%20MB%20ChB,%20MFSRH&rft.date=2014-08-01&rft.volume=28&rft.issue=6&rft.spage=903&rft.epage=915&rft.pages=903-915&rft.issn=1521-6934&rft.eissn=1532-1932&rft_id=info:doi/10.1016/j.bpobgyn.2014.05.006&rft_dat=%3Cproquest_cross%3E1553106777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1553106777&rft_id=info:pmid/24990143&rft_els_id=1_s2_0_S1521693414001060&rfr_iscdi=true |